Benzinga · Jul 27, 2026
TD Cowen Maintains Buy on Nakamoto, Raises Price Target to $17
TD Cowen analyst Lance Vitanza maintains Nakamoto (NASDAQ:NAKA) with a Buy and raises the price target from $1 to $17.
NASDAQ · NAKA
Healthcare · Medical - Equipment & Services
$4.93
Down-$0.12 (-2.38%)
Updated Aug 15, 2026, 5:37 AM
SID Score
6.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
NAKA closed at $4.93 after 21 trading sessions, up 21.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $4.97 | $5.10 | $4.79 | $4.93 | 74.41K |
| Aug 13, 2026 | $4.97 | $5.15 | $4.87 | $5.05 | 119.84K |
| Aug 12, 2026 | $5.03 | $5.072 | $4.90 | $4.94 | 47.34K |
| Aug 11, 2026 | $5.06 | $5.1199 | $4.9686 | $5.00 | 55.02K |
| Aug 10, 2026 | $4.94 | $5.08 | $4.845 | $5.04 | 93.44K |
| Aug 7, 2026 | $4.95 | $5.33 | $4.83 | $4.98 | 133.95K |
| Aug 6, 2026 | $4.84 | $5.00 | $4.71 | $4.95 | 106.5K |
| Aug 5, 2026 | $4.94 | $5.05 | $4.85 | $4.85 | 43.9K |
| Aug 4, 2026 | $4.85 | $5.20 | $4.80 | $5.07 | 97.29K |
| Aug 3, 2026 | $4.72 | $5.02 | $4.6031 | $4.85 | 72.74K |
| Jul 31, 2026 | $4.92 | $4.95 | $4.65 | $4.75 | 64.49K |
| Jul 30, 2026 | $4.40 | $4.9799 | $4.40 | $4.95 | 114.5K |
| Jul 29, 2026 | $4.465 | $4.59 | $4.185 | $4.28 | 171.69K |
| Jul 28, 2026 | $4.55 | $4.58 | $4.3205 | $4.52 | 95.23K |
| Jul 27, 2026 | $5.00 | $5.2695 | $4.42 | $4.69 | 125.4K |
| Jul 24, 2026 | $5.01 | $5.16 | $4.81 | $4.87 | 118.91K |
| Jul 23, 2026 | $4.73 | $4.99 | $4.545 | $4.97 | 237.76K |
| Jul 22, 2026 | $4.72 | $4.96 | $4.60 | $4.87 | 226.43K |
| Jul 21, 2026 | $4.67 | $5.25 | $4.66 | $4.80 | 468.55K |
| Jul 20, 2026 | $4.19 | $4.65 | $3.93 | $4.63 | 331.82K |
| Jul 17, 2026 | $3.85 | $4.24 | $3.85 | $4.06 | 210.73K |
The latest Smart Investors Daily articles mentioning NAKA.
NAKA research
Company profile and research snapshot.
Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 27, 2026 | TD Cowen | Buy | — |
| Apr 10, 2026 | TD Cowen | Buy | — |
| Apr 6, 2026 | Maxim Group | Buy | — |
| Feb 23, 2026 | B. Riley Securities | Buy | — |
| Nov 20, 2025 | B. Riley Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 27, 2026
TD Cowen analyst Lance Vitanza maintains Nakamoto (NASDAQ:NAKA) with a Buy and raises the price target from $1 to $17.
Yahoo · Jul 15, 2026
Nakamoto Inc. (NASDAQ: NAKA) surged in its latest session, closing at $3.98, a gain of 18.1%, or 61 cents, from the prior close of $3.37. The move came on about 444,580 shares changing hands, roughly 1.55 times the stock's average daily volume of 285,909, and it has held: shares ticked up another ...
Benzinga · Jun 22, 2026
Marks Significant Step in Wind-Down of Healthcare OperationsNakamoto Inc. (NASDAQ:NAKA) ("Nakamoto" or the "Company") today announced that its healthcare clinics concluded operations on June 19, 2026.
Benzinga · Feb 23, 2026
B. Riley Securities analyst Fedor Shabalin maintains Nakamoto (NASDAQ:NAKA) with a Buy and lowers the price target from $1 to $0.5.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning NAKA.